Catapult Awards

Catpult Research Strategy Infographic - Catapult Awards

Through our research programs, we are addressing the barriers that are preventing safer treatments from reaching children. Our research strategy encompasses programs and funding that deliver results to save children NOW.

The third and final phase of CureSearch’s research strategy is the Catapult Awards program. These critical awards push forward high-potential research into clinical trials and ultimately drug development.

Catapult Awards – Active Grants

Catapult Awards will provide funding support up to $5 million for a two- to three-year award period for ‘clinic-ready’ projects.


The General Catapult Award launched in October 2017 with a focus on Phase 1 or Phase 2 clinical trials testing novel, targeted agents or “repurposed” adult targeted agents for pediatric cancers. The application window is now closed and awards were announced in July 2018.

CureSearch continues to invest in large-scale awards to ensure sustainable research moves forward at an accelerated pace. We are proud to invest in work that will move the needle and impact the future of children’s treatments.

We’re excited to announce that two project awards slated for 2018/2019:

Upcoming Catapult Awards:

  • Immunotherapy Catapult Award in partnership with the Parker Institute for Cancer Immunotherapy. Read more in our Press Room. – Fall 2018
  • Molecular Targets Catapult Award – Fall 2019

Click here to be added to our mailing list to be the first to know about new RFAs.

CureSearch Catapult Awards will provide support for projects that:

  • Will advance promising therapies for pediatric cancer into or further along in clinical development
  • Show a strong potential for future approval and commercialization

Highest priority will be given to projects that address areas of high unmet needs in pediatric cancer. Catapult Awards will provide funding support up to $5 million for a two- to three-year award period, for “clinic-readyprojects that fit the following parameters:

CureSearch won’t stop until more and less-toxic children’s cancer treatments are out of the lab and into the clinic and marketplace, ensuring more children live long, healthy and productive lives.

For more information on Catapult Awards, developing resources or future RFAs, contact:
Kelli Wright
National Director, Strategic Initiatives
(240) 235-2217

Sarita Sastry, PhD
National Director, Research and Programs
(240) 235-2215

Pin It on Pinterest

Scroll to Top